---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-23-000073"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:21:14.741274+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Curis Q3 net loss $12.2M ($2.13/sh); cash $68.5M; emavusertib studies resume

## Summary
- Net loss narrowed to $12.2M from $13.3M YoY; revenue unchanged at $2.8M from Erivedge royalties.
- Cash, cash equivalents and investments total $68.5M; company expects funding into 2025.
- Patient enrollment restarted in Phase 1/2 TakeAim Leukemia and Lymphoma emavusertib studies after partial clinical hold lift.
- Plans to initiate triplet combo study of emavusertib with azacitidine and venetoclax in AML in Q4 2023.
- Updated TakeAim Lymphoma data expected at ASH December 2023; leukemia data in H1 2024.

## SEC filing metadata
- accession: 0001108205-23-000073
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/0001108205-23-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/cris-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-23-000073
- JSON: https://secwatch.observer/filing/0001108205-23-000073.json
- Plain text: https://secwatch.observer/filing/0001108205-23-000073.txt

## Key facts
- Earnings Releases
  CURIS INC reported third quarter of 2023 results: revenue $2.8 million, net income $12.2 million, EPS $2.13.
  - Period: third quarter of 2023
  - Revenue: $2.8 million
  - Net income: $12.2 million
  - EPS: $2.13
  - Result: reported results
  source text: to a net loss of $45.3 million or $9.82 per share on both a basic and diluted basis for the same period in 2022. Revenues for the third quarters of 2023 and 2022 were both $2.8 million. Revenues for both periods consist of royalty revenues from Genentech and Roche's sales of Erivedge®. Revenues for the nine months ended September 30, 2023 and 2022 were both
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000073/0001108205-23-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.